Moreover, a high concentration of CXCL12-induced tumour dormancy contributes to drug resistance, arousing the clinical value of controlling CXCL12 production and scavenging excessive CXCL12 in the bone marrow [30]. The gene discussed is CXCL12; the disease is neoplasm.